· Updated · Venture Capital Tracker · investment-strategies · 3 min read
QuantHealth’s $45M Series B: Simulate the Trial Before You Enroll Patients
Qumra Capital led QuantHealth’s $45M Series B for AI clinical-trial simulation — predicting trial outcomes before first patient in, with Sanofi Ventures returning.
VCT data record
Funding event facts
Source-backed financing and transaction details. Unknown terms remain undisclosed rather than estimated.
QuantHealth raises $45M Series B for clinical trial simulation
Qumra Capital led a $45M Series B into QuantHealth to scale AI clinical-trial simulation before first patient in, with Sanofi Ventures, Pitango HealthTech, Bertelsmann Healthcare Investments, and others participating.
- Event type
- Funding Round
- Event date
- Aug 4, 2026
- Stage / label
- Series B
- Amount
- $45M
- Confidence
- Reported
Company / target: QuantHealth
Lead: Qumra Capital
Participants: Pitango HealthTech , Sanofi Ventures , Artofin , Bertelsmann Healthcare Investments , GC Ventures , NewHealth Ventures , Shoni Top Ventures , Esplanade Ventures
Sources: fiercehealthcare.com finsmes.com
QuantHealth raised a $45 million Series B in early August 2026, led by Qumra Capital, with Sanofi Ventures, Pitango HealthTech, Bertelsmann Healthcare Investments, and others participating. The Tel Aviv company sells a blunt idea: run the trial in silico before you burn cash and patients.
Key facts
| Field | Detail |
|---|---|
| Company | QuantHealth (Tel Aviv) |
| Round | $45M Series B |
| Date | August 2026 (announced ~Aug 4) |
| Lead | Qumra Capital |
| Notable participants | Sanofi Ventures, Pitango HealthTech, BHI, Artofin, GC Ventures, others |
| Prior | $15M Series A (2023); Accenture strategic (2024) |
| Total raised | ~$70M+ (company / press) |
| Traction claim | 600+ simulated trials · ~30 indications · up to 90% predictive accuracy (company) |
Who uses the product — and for what job
Users: clinical development, biometrics, and portfolio strategy teams inside biopharma.
Job: stress-test protocol design, endpoints, and population choices before first patient in — so effectiveness/safety failure modes show up in simulation, not Phase 3.
CEO Orr Inbar’s distinction (Fierce Healthcare): most AI in the space reacts mid-trial; QuantHealth claims to shape strategy day one via patient-level biology simulation (Katina workflow).
Why now
- Clinical development is still where ~90% of candidates die — and where AI spend has lagged discovery hype.
- Sponsors face capital and time pressure; one avoided failed Phase 2/3 pays for many software seats.
- Strategic LPs (Sanofi Ventures) want tools that change decision quality, not slideware.
Why these investors — portfolio fit
Qumra (Israeli growth) + Sanofi Ventures + Bertelsmann Healthcare is a pharma-native syndicate, not a generalist AI tourist round.
Likely founder rationale: raise from capital that already understands trial economics and can open sponsor introductions — Sanofi Ventures’ Cris De Luca called simulation “an important part of the drug development toolkit.”
| Investor | Fit |
|---|---|
| Qumra | Growth for Israeli healthtech category leaders |
| Sanofi Ventures | Strategic distribution + clinical credibility |
| Pitango / BHI | Healthcare specialist diligence |
We do not currently list Qumra or Sanofi Ventures as /fund/ entities — treat names as press-sourced.
Competitive map
| Player | Lane |
|---|---|
| Trial design consultancies | Human experts; slower, less repeatable |
| RWE / claims analytics | Post-market and observational; different job |
| Discovery AI (target/molecule) | Upstream of protocol design |
| CRO optimization tools | Execution efficiency after design is locked |
Market signal
A $45M B with a strategic pharma venture arm returning says simulation-first trial design is graduating from pilot budgets into platform spend. Expansion plans (40+ indications; later commercial positioning) matter more than a single accuracy headline.
When not to overclaim
- Do not equate “up to 90% accuracy” with regulatory acceptance — label it company-reported.
- Do not confuse QuantHealth with molecule discovery AI.
- Do not assume every indication transfers; oncology ≠ rare disease without validation.
Practical takeaway
- Founders (health AI): Sell dollars of failed-trial risk avoided, with indication-level validation evidence.
- Investors: Prefer syndicates with pharma strategics when the buyer is clinical development.
- Operators (sponsors): Pilot on one asset class with pre-registered success metrics before enterprise rollout.
Sources
- Fierce Healthcare: https://www.fiercehealthcare.com/finance/quanthealth-raises-45m-series-b-accelerate-ai-driven-clinical-trial-simulations
- FinSMEs (Aug 4, 2026): https://www.finsmes.com/2026/08/quanthealth-raises-45m-in-series-b-funding.html
- Related: /2026-august-9-investment-news-roundup-agents-voice-health
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
